Page 9 - Solid Tumor News Today

Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that data will be presented from multiple studies across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, June 4-8 and the European Hematology Association (EHA) 2021 Virtual Congress, June 9-17. Data presented at ASCO and EHA include multiple company-sponsored and investigator-initiated trials, which underscore th

A mix of bottom-up and top-down approaches for Cancer Monoclonal Antibodies Market sizing, analyzing the key regional markets, dynamics, and trends fo

/Latest Update 2021: Antibody Drug Conjugate Therapeutics Market by COVID19 Impact Analysis And Top Manufacturers: Bayer AG, Pfizer, Hoffman-Le Roche, Seattle Genetics, ImmunoGen, etc. Trending Latest Update 2021: Antibody Drug Conjugate Therapeutics Market by COVID19 Impact Analysis And Top Manufacturers: Bayer AG, Pfizer, Hoffman-Le Roche, Seattle Genetics, ImmunoGen, etc. resforMay 24, 2021 Antibody Drug Conjugate Therapeutics Market : Size, Trends and Forecasts (2020-2027)”, delivers an ...

Data from Merck’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21 Saturday, May 22, 2021 12:20PM IST (6:50AM GMT)   New analyses from pivotal BAVENCIO ® study reinforce unique clinical benefits across different subgroups in the treatment of advanced urothelial carcinoma New data from VISION study of TEPMETKO ® show association between liquid biopsy-identified biomarker and clinical response in METex14 skipping NSCLC, supporting liquid biopsy as a means for moni...

April 29 Alliance for Cancer Gene Therapy Summit 2021 Features World Renowned Cancer Researchers Advancing Solid Tumor Breakthroughs Share Article James P. Allison, PhD, Carl H. June, MD and Siddhartha Mukherjee, MD Keynote the Summit Nobel Laureate James P. Allison, PhD, Carl H. June, MD and Pulitzer-prize winning author Siddhartha Mukherjee, MD will be the keynote speakers at the virtual Alliance for Cancer Gene Therapy Summit 20 It’s so rare to have the opportunity to hear from the world�...

Trillium Therapeutics is up against some stiff competition to become a leader in the new class of drugs called CD47, which turn off the “don’t eat me” signal transmitted by cancer cells, but CEO Jan Skvarka believes his biotech’s data will stand for themselves.

New Stem Cell Therapy Stops Spread of Breast Cancer by Hannah Joy on  March 8, 2021 at 6:33 PM A biology-driven, Stem-Cell therapy fights against solid tumors; especially stops brain cancer that metastasizes to the brain, reveals a new study. Approximately 15-to-30 percent of patients with metastatic breast cancer have brain metastasis (BM), with basal-like breast cancer (BLBC) metastasizing to the brain most frequently. The prognosis for BLBC-BM patients is poor, as the bloo...

Scientific breakthroughs, approvals: Latest CAR T-cell therapy related developments From new research offering promise for childrens cancer to FDA registrations, we track the progress made in the past few weeks in terms of advancing CAR T-cell therapy in a number of markets. Novartis on Friday [February 12] reported that it had received approval from Australian regulatory agency, Therapeutic Goods Administration (TGA), for Cell Therapies to manufacture and supply its...

WCCB Charlottes CW February 10, 2021 CHARLOTTE, N.C. (News Release) — Isabella Santos Foundation (ISF) a Charlotte childhood cancer charity was created in honor of Isabella Santos who lost her fight to neuroblastoma, a rare pediatric cancer, at just seven years old. On March 9th, Isabella would have turned 16-years-old. While she only lived seven years, Charlotte, the nation, and the world feel her astounding impact through the creation of the ISF Rare & Solid Tumor Program at Atrium Health L...

Share this article Share this article ResearchAndMarkets.coms offering. The fast pace of cancer prevalence and mortality rate across the globe has led to an increasing concern as well as recognition that the specific disease requires attention by the researchers. In the past few years, the type of research activities that have been conducted for cancer disease has moved several laboratory findings to the commercial world. In one of the scenarios, development of cancer biological toxins is a fo...